Table 2.
Summary of the effectiveness of the different types of vaccines.
| Type |
The effectiveness of messenger RNA-based vaccines against COVID-19 on different days |
Study ID |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| First dosea |
Second doseb |
||||||||
| ≤10 days | 11-13 days | 14-20 days | 21-27 days | ≥28 days | 7-13 days | 14-56 days | |||
| Messenger RNA vaccine | 4% (95% CI: -0.33-0.31) | 54% (95% CI: 0.33-0.69) | 59% (95% CI: 0.47-0.71) | 59% (95% CI:0.46-0.72) | 64% (95% CI: 0.29-0.99) | 97% (95% CI: 0.93-1.00) | 96% (95% CI: 0.93-1.00) | Dagan et al.[11]; Goldshtein et al.[12]; Butt et al.[13] |
|
| Inactivated vaccine | Paixao et al.[14] (Symptomatic infection)c | / | / | 5.02% (95% CI: -0.1822-0.2369) | 5.02% (95% CI: -0.1822-0.2369) | 5.02% (95% CI: -0.1822-0.2369) | / | 40.97% (0.2707-0.5222) | Enny Paixao et al.[14] |
| Paixao et al.[14] (Severe infection)c | / | / | 67.74% (95% CI: 0.20-0.87) | 67.74% (95% CI: 0.20-0.87) | 67.74% (95% CI: 0.20-0.87) | / | 85.39% (0.5944-0.9480) | ||
| Overall | / | / | 60% (95% CI: 0.49-0.71) | 60% (95% CI: 0.48-0.73) | 69% (95% CI: 0.50-0.88) | / | 96% (0.93-0.99) | Dagan et al.[11]; Goldshtein et al.[12]; Butt et al.[13] |
|
a
Different days after the first dose of vaccination.
b
Different days after the second dose of vaccination.
c
The Paixao et al.[14] (symptomatic infection) study included pregnant women who had symptomatic infections after vaccination and did not have a positive reverse transcription-polymerase chain reaction test result within the previous 90 days. The Paixao et al.[14] (severe infection) study included pregnant women with severe infections who did not have a positive reverse transcription-polymerase chain reaction test result within the previous 90 days.